Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue
+1.33%
EPS
+418.2%
Free cash flow
−6.83%
Total debt
−42.2%

Quarter to June 2026, against a year earlier

72.79 0.13 +0.18%
Market cap
$11.4B
P/E
62.2×
Fwd P/E
54.2×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
9.03% 5.34% 3.97% 3.80%

+8 more TTM periods

Piotroski F-Score
9 7 7 5
ROA
7.07% 4.22% 3.12% 2.96%
ROIC
7.70% 4.63% 3.48% 3.24%
Return on Tangible Assets
22.38% 14.27% 11.09% 11.06%
Average Days of Receivables
65.06 64.68 55.43 55.17
Free Cash Flow per Share
1.69 1.72 1.43 1.44
Free Cash Flow
263.22 269.60 223.02 224.06
Other line items

Show all line items

Columns are period end dates